Item 2.02 Results of Operations and Financial Condition.

On August 10, 2022, Harpoon Therapeutics, Inc. ("Harpoon") issued a press release announcing its financial results for the three and six month periods ended June 30, 2022. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 2.02 of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 8, 2022, Georgia L. Erbez informed Harpoon of her intention to resign from her position as Harpoon's Chief Financial Officer. Such resignation is expected to be effective as of August 31, 2022. Harpoon has initiated a replacement search, and Ms. Erbez has agreed to continue with Harpoon as a consultant to assist with the transition as needed until December 31, 2022. Harpoon and Ms. Erbez expect to enter into a consulting agreement, which will be described in a future Current Report on Form 8-K to be filed by Harpoon.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits.

Exhibit
  No.       Description

99.1          Press Release dated August 10, 2022.
104          Cover Page Interactive Data File (embedded within the Inline XBRL
        document)





                                       2

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses